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Background: Musculoskeletal manifestations affect up to 95% of SLE patients. Assessment can be problematic as not
all patients have swelling.  There is a clinical need to better select SLE patients with musculoskeletal symptoms who may
respond to therapy and assess their response. We previously analysed 100 patients with MSK symptoms and showed
that ultrasound (US) detects synovitis in patients with no clinical swelling.
Objectives: To assess the responsiveness of clinical assessment tools and US in musculoskeletal SLE.
Methods: 107 patients fulfilling ACR/SLICC criteria for SLE with musculoskeletal involvement were analysed in a cross-
sectional study.  16 of these with current inflammatory symptoms entered a pilot study of US before and after
intramuscular injection of depomedrone 120mg. These 16 patients were followed up and assessed clinically using
BILAG, SLEDAI, patient VAS, physician VAS, tender joint count, swollen joint count) and US of hand (joints and tendon
sheath) at 0, 2 and 4 weeks.
Results: Of 107 patients only 35 (32.7%) had swelling clinically at baseline but 53(49.5%) had US synovitis.  Response
in US and clinical parameters for the 16 longitudinal patients is shown in Table1.
Table 1
  Week 0 Week 2 P* Week 4 P  
BILAG-MSK n(%)
          A
          B
          C
          D
 
6/16 (37.5)
6/16 (37.5)
4/16 (25)
0/16 (0)
 
3/16 (18.7)
3/16 (18.7
5/16 (31.2)
5/16 (31.2)
   
1/16 (0.06)
2/16 (12.5)
6/16 (37.5)
6/16 (37.5)
   
BILAG improved n(%) N/A 10/16 (62.5)   13/16 (81)    
SLEDAI MSK Criterion=4 points n(%) 14/16(87.5) 10 /16  (62.5)   9 /16 (56)    
SLEDAI improved n(%)   4/14 (28.5)   5/14 (36)    
TJC(0-28) median(IQR) 8 (4.3-12.3) 4 (1.0 -13.5) 0.228 4 (1-14.8) 0.197  
SJC(0-28) median(IQR) 3 (0.3-5) 0 (0-1) 0.059 0 (0-0) 0.003  
Symptomatic joints  median(IQR) 15 (5.8-21.5) 2 (0-13) 0.047 3.5 (1-14.8) 0.066  
Patient VAS(0-100 median(IQR) 55 (30-78.5) 30 (8.8-40) 0.016 35 (10-48.8) 0.059  
Physician VAS(0-100 median(IQR) 31 (13-65.5) 23 (5-50) 0.001 21 (3.8-43.5) 0.001  
US- total PD median (IQR) 8.5 (4.8-34.8) 1 (0-6.3) 0.002 1 (0-1) 0.001  
US-total GS  median(IQR) 24 (17-46) 12.5 (5.3-23.8) 0.002 10.5 (7-13.8) 0.001  
No. joints with synovitis median(IQR) 8 (5-19.3) 3 (0.8-7.5) 0.004 2 (1-4) 0.001  
P values compare 2 and 4 weeks with baseline.  Value under .05 considered as trend, values under .025 considered
significant.
Conclusions: Although swollen joint count was responsive to change with therapy, US was more sensitive in detecting
active joints disease at baseline and showed greater and more significant change with therapy. The responsiveness of
swollen joints likely explains the responsiveness in BILAG musculoskeletal system index and physician VAS.  However,
tender and symptomatic joint counts, as well as SLEDAI, were poorly responsive to therapy.  Overall, US is the tool most
responsive to change for monitoring musculoskeletal disease activity in SLE.
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